Enlivex ENLV 深 沪
等待开盘 04-01 09:30:00 美东时间
0.9301
+0.030
+3.34%
华盛通- 最 高0.9578
- 今 开0.9201
- 成交量 33.73万股
- 最 低 0.8915
- 昨 收 0.90
- 总市值 2.21亿
- 52周最高 2.10
- 市盈率 静 0.04
- 换手率 0.14%
- 52周最低 0.66
- 委 比 61.52%
- 总股本 2.38亿
- 历史最高 44.90
- 量 比 0.12
- 振 幅 7.37%
- 历史最低 0.66
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enlivex Therapeutics Q4 EPS $26.83 Beats $(0.13) Estimate
Enlivex Therapeutics (NASDAQ:ENLV) reported quarterly earnings of $26.83 per share which beat the analyst consensus estimate of $(0.13) by 20738.46 percent. This is a 12295.45 percent increase over losses of $(0.22) per
03-25 20:39
Enlivex Receives First FDA Approval For Phase2b Trial Of Allocetra For Age-Related Osteoarthritis
The U.S. Food and Drug Administration (FDA) has cleared Enlivex's Investigational New Drug (IND) application for Allocetra, for the treatment of patients with moderate-to-severe age-related symptomatic primary knee
03-23 20:09
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex获得FDA批准启动针对中重度与年龄相关的膝关节骨关节炎患者的2b期全球多中心临床试验。该试验将评估其免疫疗法Allocetra™的疗效与安全性。此前，1/2a期临床试验已显示显著治疗效果。Enlivex采用双引擎价值创造模式，结合质量寿命项目与预测市场 treasury 策略推动发展。 Knee osteoarthritis影响数千万美国人，亟需新疗法。Trial将评估疼痛、功能及生活质量指标，以验证Allocetra™的潜力。
03-23 12:00
Enlivex Rebrands as Enlivex Ltd. Following Shareholder Approval
An announcement from Enlivex ( ($ENLV) ) is now available. On February 3, 2026,...
02-23 21:50
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
Enlivex Therapeutics Ltd. announced the listing of its RAIN token on Kraken, the second-largest U.S.-based cryptocurrency exchange, on February 9, 2026. This listing aims to increase token access, enhance liquidity, and improve price discovery for RAIN. Kraken, with over 5.7 million users and $2 trillion in trading volume in 2025, is known for its security, regulatory compliance, and institutional-grade market participation. Rain serves as the go...
02-10 13:00
Enlivex Lists RAIN Treasury Token on WhiteBIT to Boost Liquidity
Enlivex ( ($ENLV) ) has provided an update. On January 26, 2026, Enlivex announ...
01-26 21:27
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
Enlivex Therapeutics Ltd. announced the listing of its primary treasury asset, the RAIN token, on the WhiteBIT cryptocurrency exchange, enhancing market access and liquidity for RAIN. RAIN is a governance and utility token for a decentralized predictions and options protocol on the Arbitrum network. Enlivex focuses on late-stage clinical development of Allocetra™ for treating osteoarthritis, impacting millions globally with limited treatment opti...
01-26 13:00
Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
Enlivex Therapeutics Ltd. announced its plan to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE) to streamline operations, reduce administrative costs, and enhance liquidity on Nasdaq. The last day of trading on TASE is expected to be April 23, 2026, with delisting on April 26, 2026. The shares will remain listed on Nasdaq under the symbol "ENLV," and the company will continue filing SEC reports. The move aims to foc...
01-23 13:00
Analyst Sees Massive Upside For Penny Stock Enlivex After RAIN Token Gains Momentum
Enlivex's RAIN token begins trading on KuCoin as analysts raise price targets, citing growing prediction markets and token burn mechanics.
01-15 00:46
